Literature DB >> 22780858

Dravet syndrome: seizure control and gait in adults with different SCN1A mutations.

Jennifer J Rilstone1, Fernando M Coelho, Berge A Minassian, Danielle M Andrade.   

Abstract

PURPOSE: Dravet syndrome (DS) is an aggressive epileptic encephalopathy. Pharmacoresistant seizures of several types plague most patients with DS throughout their lives. Gait difficulties are a common, but inconsistent finding. The majority of cases are caused by mutations in the SCN1A gene, but little information is available about how particular mutations influence the adult phenotype. The purpose of this study is to correlate different types of SCN1A mutations and (1) seizure control, (2) occurrence of convulsive status epilepticus (cSE), and (3) the presence of crouch gait in adult patients.
METHODS: In a cohort of 10 adult patients with DS caused by SCN1A mutations, we investigated seizure frequency, history of cSE, and gait. All patients were identified in the epilepsy clinic between 2009 and 2011. SCN1A mutations were divided into four different groups based on location or effect of the mutation. Retrospective chart review and recent physical examination were completed in all cases. KEY
FINDINGS: All patients had a pathogenic mutation in the SCN1A gene. Four SCN1A mutations have not been described previously. Greater than 90% seizure reduction was observed (compared to childhood frequency) in six of seven patients with missense mutations in the pore-forming region (PFR) of the Na(v) 1.1 protein (group A) and nonsense mutations (group B). One patient with a splice-site mutation (group C) and another with a mutation outside the PFR (group D) became free of all types of seizures. cSE after the age of 19 years was observed in only one patient. Crouch gait, without spasticity, is identified as an element of the adult DS phenotype. However, only one half of our adult DS cohort demonstrated crouch gait. This feature was observed in five of seven patients from groups A and B. SIGNIFICANCE: This study shows that seizure control improves and cSE become less frequent in DS as patients age, independent of their SCN1A mutation type. Complete seizure freedom was seen in two patients (groups C and D). Finally, this study shows that in DS, crouch gait can be observed in up to 50% of adults with SCN1A mutation. Although no definite statistical correlations could be made due to the small number of patients, it is interesting to note that crouch gait was observed only in those patients with nonsense mutations or mutations in the PFR. Future studies with larger cohorts will be required to formally assess an association of gait abnormalities with particular SCN1A mutations. Wiley Periodicals, Inc.
© 2012 International League Against Epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22780858     DOI: 10.1111/j.1528-1167.2012.03583.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  13 in total

1.  Impaired excitability of somatostatin- and parvalbumin-expressing cortical interneurons in a mouse model of Dravet syndrome.

Authors:  Chao Tai; Yasuyuki Abe; Ruth E Westenbroek; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

2.  Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome.

Authors:  Alfonso Fasano; Felippe Borlot; Anthony E Lang; Danielle M Andrade
Journal:  Neurology       Date:  2014-05-21       Impact factor: 9.910

Review 3.  Current Treatment Strategies and Future Treatment Options for Dravet Syndrome.

Authors:  Julie Ziobro; Krista Eschbach; Joseph E Sullivan; Kelly G Knupp
Journal:  Curr Treat Options Neurol       Date:  2018-10-13       Impact factor: 3.598

Review 4.  Pharmacotherapy for Dravet Syndrome.

Authors:  Adam Wallace; Elaine Wirrell; Daniel L Kenney-Jung
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

5.  Phenotypic and Genotypic Characteristics of SCN1A Associated Seizure Diseases.

Authors:  Chunhong Chen; Fang Fang; Xu Wang; Junlan Lv; Xiaohui Wang; Hong Jin
Journal:  Front Mol Neurosci       Date:  2022-04-28       Impact factor: 5.639

Review 6.  Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy.

Authors:  Lori L Isom; Kelly G Knupp
Journal:  Neurotherapeutics       Date:  2021-08-10       Impact factor: 6.088

7.  The relation of etiology based on the 2017 ILAE classification to the effectiveness of the ketogenic diet in drug-resistant epilepsy in childhood.

Authors:  Markus Breu; Chiara Häfele; Petra Trimmel-Schwahofer; Wolfgang M Schmidt; Franco Laconne; Julia Vodopiutz; Christoph Male; Anastasia Dressler
Journal:  Epilepsia       Date:  2021-08-28       Impact factor: 6.740

8.  Progressive Worsening of Gait and Motor Abnormalities in Older Adults With Dravet Syndrome.

Authors:  Arunan Selvarajah; Carolina Gorodetsky; Paula Marques; Quratulain Zulfiqar Ali; Anne T Berg; Alfonso Fasano; Danielle M Andrade
Journal:  Neurology       Date:  2022-04-13       Impact factor: 11.800

9.  Influence of common SCN1A promoter variants on the severity of SCN1A-related phenotypes.

Authors:  Iris M de Lange; Wout Weuring; Ruben van 't Slot; Boudewijn Gunning; Anja C M Sonsma; Mark McCormack; Carolien de Kovel; Lisette J J M van Gemert; Flip Mulder; Marjan J A van Kempen; Nine V A M Knoers; Eva H Brilstra; Bobby P C Koeleman
Journal:  Mol Genet Genomic Med       Date:  2019-05-29       Impact factor: 2.183

10.  Evaluation of Presumably Disease Causing SCN1A Variants in a Cohort of Common Epilepsy Syndromes.

Authors:  Dennis Lal; Eva M Reinthaler; Borislav Dejanovic; Patrick May; Holger Thiele; Anna-Elina Lehesjoki; Günter Schwarz; Erik Riesch; M Arfan Ikram; Cornelia M van Duijn; Andre G Uitterlinden; Albert Hofman; Hannelore Steinböck; Ursula Gruber-Sedlmayr; Birgit Neophytou; Federico Zara; Andreas Hahn; Padhraig Gormley; Felicitas Becker; Yvonne G Weber; Maria Roberta Cilio; Wolfram S Kunz; Roland Krause; Fritz Zimprich; Johannes R Lemke; Peter Nürnberg; Thomas Sander; Holger Lerche; Bernd A Neubauer
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.